8-K: Celularity Divests Biomaterials, Secures $13.3M, Faces Default Notice

Celularity Inc. announced an amendment to its asset purchase and license agreement with NexGel, Inc., receiving $13.3 million and potential future milestones, while also addressing a default notice from Helena regarding a convertible note.

Summary

• Celularity Inc. amended its Asset Purchase and Exclusive License Agreement with NexGel, Inc., receiving $13.3 million in aggregate consideration, comprising an $8.3 million upfront cash payment and a $5.0 million convertible promissory note.
• The agreement includes a first milestone payment of $2.5 million contingent on achieving $25.0 million in net sales or reaching 15 months post-commencement date with at least $15.0 million in net sales.
• NexGel will assume all sales representative obligations, and the product purchase credit was terminated.
• The outside date for the agreement was extended from April 15, 2026, to April 30, 2026.
• Helena Global Investment Opportunities 1 Ltd. delivered an exchange notice to convert Series A Convertible Preferred Stock into a convertible promissory note, which Helena later declared in default, citing the company's failure to file its Annual Report on Form 10-K on time.
• The company believes the default stems from its delinquency in filing its 2025 Annual Report and is evaluating the notice, intending to cure the asserted default within the five-business-day cure period.
• Celularity implemented organizational changes, terminating the employment of Senior Vice President John R. Haines and accepting the resignation of President, Degenerative Diseases, Stephen A. Brigido.
• The company issued a press release on April 21, 2026, announcing the amendment and related developments with NexGel.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant default notice from a key lender and the departure of senior management, overshadowing the positive aspects of the NexGel transaction.

Positives

• Received $13.3 million in aggregate consideration from NexGel, including $8.3 million in cash and a $5.0 million convertible promissory note.
• Potential to receive up to $20.0 million in future milestone payments and royalties on net sales.
• Retired nearly $13.0 million of debt, strengthening the balance sheet and capital position.
• Monetized non-core biomaterials assets to focus resources on its longevity-focused therapeutic pipeline and manufacturing platform.

Negatives

• Received a notice of event of default from Helena Global Investment Opportunities 1 Ltd. regarding a convertible promissory note.
• The asserted default is due to the company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
• If the default is not cured within five business days, Helena may declare the Mandatory Default Amount (115% of outstanding principal, interest, and other amounts) due and payable.
• Following an event of default, outstanding principal accrues interest at a rate of 15% per annum, compounded annually.
• Termination of employment for Senior Vice President John R. Haines and resignation of President, Degenerative Diseases, Stephen A. Brigido, indicating organizational changes and potential restructuring.

Risks

• Failure to cure the asserted default within the five-business-day period could lead to Helena declaring the full amount of the note due and payable, plus a 15% default interest rate.
• NexGel's commercialization of licensed products and achievement of royalty and milestone thresholds are subject to substantial risks and uncertainties.
• The company's ability to realize the anticipated strategic and financial benefits of the NexGel transaction is subject to risks.
• The company's failure to comply with reporting requirements of the Securities Exchange Act of 1934, including becoming delinquent in filings, constitutes an event of default.

Future Outlook

Celularity Inc. is advancing its longevity-focused therapeutic pipeline and scalable manufacturing platform following the divestiture of its biomaterials business. The company is eligible to receive future milestone payments and royalties from NexGel, subject to performance metrics. The company is also focused on curing the asserted default with Helena to avoid acceleration of the note and associated penalties.

Management Comments

• "This transaction with NexGel marks an important step in Celularitys ongoing efforts to sharpen strategic focus, monetize non-core biomaterials assets and strengthen Celularitys capital position as we advance our longevity-focused strategy."
• "By streamlining our biomaterials activities while retaining the opportunity to participate in future milestone and royalty economics, we are further aligning resources around high-value cellular therapeutics and other programs targeting the fundamental mechanisms of aging."

Industry Context

StockSavvy.ai notes that Celularity's strategic shift to focus on its core cell therapy pipeline and manufacturing, while divesting non-core biomaterials assets, aligns with a broader industry trend of companies streamlining operations to concentrate on high-potential therapeutic areas. The monetization of assets and debt reduction are critical for companies in the regenerative medicine space, which often require significant capital for R&D and clinical trials.

Comparison to Industry Standards

• The $13.3 million upfront consideration for the biomaterials assets and license appears moderate, with potential upside from milestones and royalties. Comparable divestitures in the biotech sector vary widely based on the stage of development and market potential of the divested assets.
• The $5.0 million convertible note from NexGel is a common financing instrument in such transactions, allowing for deferred payment and potential equity conversion, though the terms (18-month term) are standard.
• The default notice from Helena, triggered by a late SEC filing, highlights the critical importance of regulatory compliance for publicly traded companies, especially those with convertible debt instruments. Industry standard practice mandates timely filings to avoid triggering default clauses.

Management Changes

Legal Proceedings

• Helena Global Investment Opportunities 1 Ltd. has asserted an event of default under the Helena Note, citing, among other things, the Company's failure to comply with reporting requirements of the Securities Exchange Act of 1934, including becoming delinquent in its filings.

Stakeholder Impact

• Shareholders: Potential negative impact due to the default notice, risk of note acceleration, and executive departures, which could affect stock price and future dilution if a capital raise is needed to cover debt obligations. Positive impact from the monetization of non-core assets and debt reduction.
• Creditors: Increased risk for Helena Global Investment Opportunities 1 Ltd. if the default is not cured, potentially leading to accelerated repayment or default interest. Other creditors may face increased risk if the company's financial position deteriorates.
• Employees: Potential impact from organizational changes and executive departures, which could signal restructuring or shifts in strategic direction.
• Suppliers: No direct impact mentioned, but potential indirect impact if the company's financial stability is affected.

Next Steps

• Celularity intends to cure the asserted default with Helena within the applicable cure period.
• NexGel will assume sales representative obligations and begin commercializing licensed products.
• Celularity will continue to focus resources on advancing its longevity-focused therapeutic pipeline and manufacturing platform.
• The company will monitor net sales to determine eligibility for milestone payments from NexGel.

Key Dates

Recommendation

The NexGel transaction provides some positive financial and strategic benefits, including asset monetization and debt reduction. However, the significant negative event of a default notice from a key lender due to a late SEC filing, coupled with executive departures, introduces substantial risk and uncertainty. A 'hold' recommendation is appropriate pending clarification and resolution of the default situation and a clearer outlook on the company's ability to meet its financial and reporting obligations.

Keywords

Celularity Inc., NexGel, Inc., Asset Purchase Agreement, License Agreement, Convertible Promissory Note, Default Notice, Biomaterials, Longevity Therapeutics